Cysteine prodrugs
    2.
    发明授权
    Cysteine prodrugs 有权
    半胱氨酸前药

    公开(公告)号:US09457014B2

    公开(公告)日:2016-10-04

    申请号:US14391785

    申请日:2012-07-30

    摘要: Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.

    摘要翻译: 新型半胱氨酸前药及其用于治疗疾病和/或病症,包括但不限于中枢神经系统(CNS)的疾病和/或病症,包括但不限于精神分裂症,药物渴求,药物成瘾,双相情感障碍 ,焦虑症,抑郁症,帕金森病,阿尔茨海默病,认知功能障碍,多发性硬化,肌萎缩性侧索硬化(ALS),缺血性卒中,艾滋病毒痴呆和亨廷顿疾病。

    Cysteine Prodrugs
    10.
    发明申请
    Cysteine Prodrugs 审中-公开
    半胱氨酸前药

    公开(公告)号:US20160287563A1

    公开(公告)日:2016-10-06

    申请号:US15174410

    申请日:2016-06-06

    IPC分类号: A61K31/426

    摘要: Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.

    摘要翻译: 新型半胱氨酸前药及其用于治疗疾病和/或病症,包括但不限于中枢神经系统(CNS)的疾病和/或病症,包括但不限于精神分裂症,药物渴求,药物成瘾,双相情感障碍 ,焦虑症,抑郁症,帕金森病,阿尔茨海默病,认知功能障碍,多发性硬化,肌萎缩性侧索硬化(ALS),缺血性卒中,艾滋病毒痴呆和亨廷顿疾病。